Abstract:The anti‐inflammatory and neuroprotective mechanisms of the novel drug LIGc in models of neuroinflammation and cerebral ischemic injury involve its ability to downregulate the expression of the FPR1/NLRP3 signaling pathway in microglia/macrophages. This regulation facilitates the transformation of these cells into an anti‐inflammatory phenotype, leading to inhibition of pro‐inflammatory factor release and promotion of anti‐inflammatory factor production. Background Microglia/macrophages, as pivotal immune cells in the central nervous system (CNS), play a critical role in neuroinflammation associated with ischemic brain injury. Targeting their activation through pharmacological interventions represents a promising strategy to alleviate neurological deficits, thereby harboring significant implications for the prevention and treatment of ischemic stroke. Ligusticum cycloprolactam (LIGc), a novel monomeric derivative of traditional Chinese medicine, has shown potential as a therapeutic agent; however, its specific role in cerebral ischemic injury remains unclear. Methods In vitro experiments utilized lipopolysaccharide (LPS)‐induced inflammation models of RAW264.7 cells and primary mouse microglia. In vivo studies employed LPS‐induced neuroinflammation models in mice and a transient middle cerebral artery occlusion (tMCAO) mouse model to evaluate the impact of LIGc on neuroinflammation and microglia/macrophage phenotypic alterations. Further elucidation of the molecular mechanisms underlying these effects was achieved through RNA‐Seq analyses. Results LIGc exhibited the capacity to attenuate LPS‐induced production of pro‐inflammatory markers in macrophages and microglia, facilitating their transition to an anti‐inflammatory phenotype. In models of LPS‐induced neuroinflammation and tMCAO, LIGc ameliorated pathological behaviors and neurological deficits while mitigating brain inflammation. RNA‐seq analyses revealed formyl peptide receptor 1 (FPR1) as a critical mediator of LIGc's effects. Specifically, FPR1 enhances the pro‐inflammatory phenotype of microglia/macrophages and inhibits their anti‐inflammatory response by upregulating NLR family pyrin domain protein 3 (NLRP3) inflammasomes, thus aggravating inflammatory processes. Conversely, LIGc exerts anti‐inflammatory effects by downregulating the FPR1/NLRP3 signaling axis. Furthermore, FPR1 overexpression or NLRP3 agonists reversed the effects of LIGc observed in this study. Conclusion Our findings suggest that LIGc holds promise in improving ischemic brain injury and neuroinflammation through modulation of microglia/macrophage polarization. Mechanistically, LIGc attenuates the pro‐inflammatory phenotype and promotes the anti‐inflammatory phenotype by targeting the FPR1/NLRP3 signaling pathway, ultimately reducing inflammatory responses and mitigating neurological damage.

A Novel Compound Ligusticum Cycloprolactam Alleviates Neuroinflammation After Ischemic Stroke via the FPR1/NLRP3 Signaling Axis

Mechanism of ligusticum cycloprolactam against neuroinflammation based on network pharmacology and experimental verification

Prolyl hydroxylase inhibitor FG-4592 alleviates neuroinflammation via HIF-1/BNIP3 signaling in microglia

Neuroprotective role of Z-ligustilide against forebrain ischemic injury in ICR mice

A Newly-Synthesized Compound CP-07 Alleviates Microglia-Mediated Neuroinflammation and Ischemic Brain Injury Via Inhibiting STAT3 Phosphorylation.

Pharmacological Upregulation of Microglial Lipid Droplet Alleviates Neuroinflammation and Acute Ischemic Brain Injury

Ligustilide ameliorates hippocampal neuronal injury after cerebral ischemia reperfusion through activating PINK1/Parkin-dependent mitophagy

Activation of LRP1 Ameliorates Cerebral Ischemia/Reperfusion Injury and Cognitive Decline by Suppressing Neuroinflammation and Oxidative Stress through TXNIP/NLRP3 Signaling Pathway in Mice

Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway

JLX001 Ameliorates Cerebral Ischemia Injury by Modulating Microglial Polarization and Compromising NLRP3 Inflammasome Activation Via the NF-κB Signaling Pathway

GLP-1R knockdown abrogates the protective effects of liraglutide on ischaemic stroke via inhibition of M2 polarisation and activation of NLRP3 inflammasome by reducing Nrf2 activation

Isoliquiritigenin attenuates neuroinflammation after subarachnoid hemorrhage through inhibition of NF‐κB‐mediated NLRP3 inflammasome activation

Klotho upregulation contributes to the neuroprotection of ligustilide against cerebral ischemic injury in mice

The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia

Gualou Guizhi Granule Suppresses LPS-Induced Inflammatory Response of Microglia and Protects Against Microglia-Mediated Neurotoxicity in HT-22 Via Akt/NF-κB Signaling Pathways

The combination of Astragalus membranaceus and ligustrazine mitigates cerebral ischemia-reperfusion injury via regulating NR2B-ERK/CREB signaling

Dl-3-n-Butylphthalide Reduced Neuroinflammation by Inhibiting Inflammasome in Microglia in Mice after Middle Cerebral Artery Occlusion

Activation of Glucagon-Like Peptide-1 Receptor in Microglia Attenuates Neuroinflammation-Induced Glial Scarring Via Rescuing Arf and Rho GAP Adapter Protein 3 Expressions after Nerve Injury.

Inhibition of phospholipase D promotes neurological function recovery and reduces neuroinflammation after spinal cord injury in mice

A Novel SIRT6 Activator Ameliorates Neuroinflammation and Ischemic Brain Injury Via EZH2/FOXC1 Axis

Cerebrolysin Ameliorates Focal Cerebral Ischemia Injury Through Neuroinflammatory Inhibition via CREB/PGC-1α Pathway